Day One Biopharmaceuticals (DAWN) Projected to Post Quarterly Earnings on Tuesday

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data after the market closes on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.35) per share and revenue of $35.55 million for the quarter.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.11. The firm had revenue of $30.76 million during the quarter, compared to analysts' expectations of $30.28 million. Day One Biopharmaceuticals had a negative return on equity of 14.98% and a negative net margin of 42.66%. On average, analysts expect Day One Biopharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Day One Biopharmaceuticals Trading Down 0.8%

DAWN stock traded down $0.06 during trading on Friday, hitting $7.16. 423,917 shares of the company's stock were exchanged, compared to its average volume of 1,267,344. The business has a 50-day moving average price of $6.63 and a two-hundred day moving average price of $8.46. The stock has a market capitalization of $725.23 million, a price-to-earnings ratio of -10.08 and a beta of -1.27. Day One Biopharmaceuticals has a 52-week low of $6.08 and a 52-week high of $16.76.

Insider Buying and Selling at Day One Biopharmaceuticals

In other news, CEO Jeremy Bender sold 13,964 shares of the company's stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $6.26, for a total transaction of $87,414.64. Following the completion of the sale, the chief executive officer owned 145,737 shares in the company, valued at $912,313.62. This represents a 8.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Charles N. York II sold 4,282 shares of the company's stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $6.26, for a total value of $26,805.32. Following the sale, the chief financial officer owned 265,231 shares of the company's stock, valued at $1,660,346.06. This trade represents a 1.59% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 26,725 shares of company stock worth $167,299. 6.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Large investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. raised its stake in shares of Day One Biopharmaceuticals by 232.4% during the first quarter. Goldman Sachs Group Inc. now owns 1,569,918 shares of the company's stock worth $12,449,000 after purchasing an additional 1,097,679 shares during the last quarter. Millennium Management LLC raised its stake in shares of Day One Biopharmaceuticals by 587.2% during the first quarter. Millennium Management LLC now owns 1,320,095 shares of the company's stock worth $10,468,000 after purchasing an additional 1,127,995 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of Day One Biopharmaceuticals by 601.4% during the first quarter. AQR Capital Management LLC now owns 618,627 shares of the company's stock worth $4,906,000 after purchasing an additional 530,429 shares during the last quarter. Royal Bank of Canada grew its holdings in Day One Biopharmaceuticals by 40.4% during the first quarter. Royal Bank of Canada now owns 185,733 shares of the company's stock worth $1,474,000 after acquiring an additional 53,459 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Day One Biopharmaceuticals by 6.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,992 shares of the company's stock worth $302,000 after acquiring an additional 2,149 shares during the period. Hedge funds and other institutional investors own 87.95% of the company's stock.

Analyst Ratings Changes

Several research firms recently weighed in on DAWN. Needham & Company LLC decreased their target price on Day One Biopharmaceuticals from $30.00 to $27.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. HC Wainwright restated a "buy" rating and set a $36.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, April 3rd. Finally, Wedbush restated an "outperform" rating and set a $25.00 target price on shares of Day One Biopharmaceuticals in a research note on Wednesday, May 7th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Day One Biopharmaceuticals presently has a consensus rating of "Buy" and an average price target of $29.00.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.